Avanir Pharmaceuticals Pays More than $108 Million to Settle Kickback Violations

• Published date: 23 October 2019
• Subject Matter: Compliance,Whistleblowers,OIG,Anti-Kickback Statute,Kickbacks,Medical Devices,Qui Tam,Criminal Prosecution,Corruption,White Collar Crimes,Healthcare Fraud,Enforcement Actions,Physicians,Deferred Prosecution Agreements,Prescription Drugs,Corporate Integrity Agreement,Internal Controls,Long Term Care Facilities,Prescription Drug Coverage,Criminal Conspiracy,Health Care Providers,Cooperation,Fraudulent Marketing,False Claims Act (FCA),Pharmaceutical Industry,Dementia,Department of Health and Human Services (HHS)
• Law Firm: Michael Volkov